AI ScreeningAI ChatPricing
  1. JP-listed companies
  3. Financials
  4. Cash and cash equivalents

【JP:4892】

Market cap
¥5.1B
P/E ratio
-5.6x
Cyfuse develops 3D tissues and organs made entirely from human cells for regenerative medicine, drug discovery, and medical device applications.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Dec 31, 20253,727+22.08%
Dec 31, 20243,053-21.20%
Dec 31, 20233,874-12.70%
Dec 31, 20224,437+83.89%
Dec 31, 20212,413+16.41%
Dec 31, 20202,073

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)